ReShape Lifesciences (RSLS) - 2024 Q3 - Quarterly Results

Revenue Performance - Revenue increased by 16.6% in Q3 2024 compared to Q2 2024, totaling $2.3 million, and a 6.4$2,292,000, representing an increase of 6.4% compared to $2,155,000 for the same period in 2023[27] Operating Expenses - Operating expenses decreased by 40.6$3,200,000 for the three months ended September 30, 2024, from $5,168,000 in the prior year, primarily due to reduced sales and marketing expenses[27] - General and administrative expenses decreased by 30.4$6.1 million, driven by reductions in professional services and payroll-related expenditures[14] - Sales and marketing expenses decreased by 59.9% in Q3 2024 to $0.7 million, reflecting a shift to targeted digital marketing campaigns[12] - The company reported a significant reduction in sales and marketing expenses to$719,000 for the three months ended September 30, 2024, down from $1,791,000 in the same period last year[27] - Research and development expenses decreased by 26.4$0.4 million, primarily due to reduced payroll and consulting services[15] - Research and development expenses were $399,000 for the three months ended September 30, 2024, compared to$542,000 in the prior year, indicating a focus on cost management[27] Financial Performance - The net loss for the three months ended September 30, 2024, was $1,581,000, compared to a net loss of$3,534,000 for the same period in 2023, reflecting improved financial performance[27] - Cash and cash equivalents decreased to $743,000 as of September 30, 2024, down from$4,459,000 at the end of 2023, indicating liquidity challenges[26] - Total current assets fell to $5,338,000 as of September 30, 2024, compared to$10,296,000 at December 31, 2023, highlighting a decline in asset base[26] - Total liabilities increased to $4,128,000 as of September 30, 2024, from$4,000,000 at the end of 2023, suggesting rising financial obligations[26] Strategic Developments - The company received a supplementary grant of approximately $241,000 from the NIH for the development of next-generation electrodes for the DBSN™ device[3] - A merger agreement was entered into with Vyome Therapeutics, with existing ReShape stockholders expected to own approximately 11.1$5.16 million in cash, involving the sale of key assets including the Lap-Band® System and the DBSN™ System[6] - Health Canada approved the next-generation Lap-Band® 2.0 FLEX, marking a significant milestone for the company's product offerings[2] Compliance and Guidance - The company regained compliance with Nasdaq following a 1-for-58 reverse stock split effective September 23, 2024[8] - The company has not provided specific guidance for future performance but has indicated ongoing efforts to improve operational efficiency and reduce costs[27]